Aug 11, 2026, 10:52 by R. Corey Waller, MD, MS, FACEP, DFASAM

Dr. Katia Cnop of USC Street Medicine examines patient-centered approaches to opioid and stimulant use disorder care for people experiencing unsheltered homelessness, including direct-to-inject buprenorphine protocols, stimulant use disorder treatment, and the barriers that street medicine programs are working to overcome.

Aug 6, 2026, 11:52 by ASAM Weekly Editors

Is there anything better than a brand-new federal dataset? The Substance Abuse and Mental Health Services Administration (SAMHSA) recently released findings from the 2025 National Survey on Drug Use and Health (NSDUH) and they do not disappoint. From fresh figures for our slides to encouraging drops in conditions such as alcohol use disorder (AUD) rates, this report gives us the clearest snapshot yet of the post-pandemic behavioral health landscape.

Jul 31, 2026, 17:03 by Sarah Shelson

On July 30, 2026, ASAM submitted comments to the US Department of Health and Human Services (HHS) regarding the proposed temporary scheduling of 7-hydroxymitragynine (7-OH).

Jul 30, 2026, 10:39 by ASAM Weekly Editors

Methamphetamine use disorder remains a significant public health issue with high rates of morbidity and mortality and the absence of any United States Food and Drug Administration (FDA)-approved treatments. Therefore, the original report from the NIDA Clinical Trials Network (CTN) ADAPT-2 trial was an important milestone, demonstrating that extended-release naltrexone plus bupropion outperformed placebo in adults with moderate to severe methamphetamine use disorder. Yet, overall improvement remained modest, with only 16.5% of participants meeting the initial treatment response threshold.

Jul 29, 2026, 17:52 by Sarah Shelson

Jul 28, 2026, 08:00 by R. Corey Waller, MD, MS, FACEP, DFASAM

Methamphetamine use disorder remains a significant public health issue with high rates of morbidity and mortality and the absence of any United States Food and Drug Administration (FDA)-approved treatments.

Jul 27, 2026, 13:59 by Sarah Shelson

Jul 22, 2026, 14:58 by ASAM Weekly Editors

Alcohol is our lead this week, anchored by a compelling new study tracking "Trends in Alcohol-Related Deaths in the United States Over 55 Years." While recent 2020s data offered some encouraging signals regarding use and impact, this long-term analysis reveals that alcohol-related mortality has increased substantially over more than five decades, with specific demographics bearing a disproportionate burden.

Jul 21, 2026, 16:22 by Sarah Shelson

On May 20, the Centers for Medicare & Medicaid Services (CMS) issued a proposed rule that would set caps on Medicaid Managed Care State Directed Payments and Medicaid Fee-for-Service Targeted Practitioner Payments.

Jul 15, 2026, 14:19 by ASAM Weekly Editors

Initiating buprenorphine for opioid use disorder (OUD) in outpatient settings is more difficult for patients using fentanyl. There are research and published literature supporting this trend.

Jul 14, 2026, 08:00 by R. Corey Waller, MD, MS, FACEP, DFASAM

Explore how long-acting injectable buprenorphine (LAIB) provides a barrier-free way to initiate OUD treatment for patients using fentanyl.

Jul 13, 2026, 07:39 by Sarah Shelson

On July 13, the American Society of Addiction Medicine (ASAM) submitted a public comment to the White House Office of Management and Budget (OMB) in response to its proposed rule that would significantly alter Uniform Guidance governing federal grants, many of which are used to fund scientific research.

Jul 9, 2026, 07:07 by Sarah Shelson

The ASAM 2026 Mid-Year Report: Trends in Addiction Medicine State Legislation recaps major trends in addiction-related state policy.

Jul 8, 2026, 17:24 by Sarah Shelson

On July 3, the American Society of Addiction Medicine (ASAM) submitted a letter to the Department of Health and Human Services (HHS) in response to its request for information (RFI) on the chronic disease of addiction.

Jul 7, 2026, 23:22 by ASAM Weekly Editors

From the rescheduling of cannabis and the surging prevalence of nicotine pouches like Zyn, to the structural setbacks face-to-face with the alcohol industry, our field is moving at a breakneck pace.

Jul 6, 2026, 13:15 by Sarah Shelson

Jul 1, 2026, 12:35 by Sarah Shelson

Jun 30, 2026, 23:55 by ASAM Weekly Editors

One last commentary as EIC.

Jun 25, 2026, 14:14 by Sarah Shelson

Jun 24, 2026, 10:30 by ASAM Weekly Editors

Social Media Use Trajectories and Substance Use Experimentation